Duke’s commitment to partnerships across the state took four undergraduate global health majors to Pamlico County this summer. There they worked to address health disparities and disaster readiness.

A new Duke Cancer Institute research program co-led by Meira Epplein, PhD, and Katharine Garman, MD, brings together physicians, cancer biologists, epidemiologists, and biostatisticians to develop new ways to identify people at increased risk of cancer — specifically stomach cancer in Black community populations — and to “intercept” the disease before it has a chance to become established.

Health systems face elevated threats from cyberattacks. A new perspective piece written by Duke Clinical Research Institute Chief Science and Digital Officer Eric Perakslis, PhD, and published in the New England Journal of Medicine (NEJM) offers a clinicians’ guide to cybersecurity. In “Responding to the Escalating Cybersecurity Threat in Health Care,” Perakslis offers actionable insights to help health care providers protect themselves and their patients from the threats of cyberattacks.

Senior author Ann Marie Pendergast, Ph.D., and researchers from Duke Cancer Institute found a drug approved to treat leukemia successfully disrupted the ability of HER2-positive breast cancer tumors from colonizing the brain.

A new study comparing discharged COVID-19 hospital patients to discharged patients who were hospitalized for other reasons showed the COVID patients were 45% more likely to experience heart failure within a year following their discharge.

Duke-NUS Medical School has admitted 72 students to its 16th cohort of the MD program.

In this Op-ed, Camille Robinson, a fourth-year medical student, 2021-22 North Carolina Albert Schweitzer Fellow, and co-founder of the Black Maternal Health Equity Initiative at the School of Medicine, issues a call to action to address racial disparities.

Five School of Medicine faculty were among the recipients of funding from the inaugural Duke Science and Technology (DST) Launch Seed Grant Program.

The Duke Center for Brain and Spine Metastasis (DCBSM) has become one of the most comprehensive destination programs in the country for treating the growing population of patients whose cancer has spread to the brain, spine, and other parts of the central nervous system. 

The Division of Nuclear Medicine and Radiotheranostics at Duke Health has been named a Comprehensive Radiopharmaceutical Therapy Center of Excellence. Duke is one of only 14 centers in the U.S. to receive this recognition.